Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma

Drugs of Today

Volumn 51, Issue 8, 2015, Pages 491-504

  Cheng, T ^a   Grasse, L ^a   Shah, J ^a   Chandra, J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Histone deacetylase; Histone deacetylase inhibitors; LBH 589; Multiple myeloma; Panobinostat

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; DOXORUBICIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; IXAZOMIB; LENALIDOMIDE; MELPHALAN; MICRORNA; PANOBINOSTAT; PREDNISONE; THALIDOMIDE; ZOLEDRONIC ACID; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; EPIGENETICS; GASTROINTESTINAL TOXICITY; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; GENETIC EPIGENESIS; GENETICS;

EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MULTIPLE MYELOMA;

EID: 84942605310     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2015.51.8.2362311     Document Type: Article

References (90)

1. Van Speybroeck, L. From epigenesis to epigenetics: the case of C. H. Waddington. Ann N Y Acad Sci 2002, 981(1): 61-81.
2. Allis, C.D., Jenuwein, T., Reinberg, D. Epigenetics. Second ed. Cold Spring Harbor Laboratory Press: Cold Spring, Harbor, NY 2007.
3. Kornberg, R.D. Structure of chromatin. Annu Rev Biochem 1977, 46: 931-54.
4. Luo, R.X., Dean, D.C. Chromatin remodeling and transcriptional regulation. J Natl Cancer Inst 1999, 91(15): 1288-94.
5. Taverna, S.D., Li, H., Ruthenburg, A.J., Allis, C.D., Patel, D.J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 2007, 14(11): 1025-40.
6. Esteller, M. Epigenetics in cancer. N Engl J Med 2008, 358(11): 1148-59.
7. Shahbazian, M.D., Grunstein, M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007, 76: 75-100.
8. Dawson, M.A., Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150(1): 12-27.
9. Choudhary, C., Kumar, C., Gnad, F. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325(5942): 834-40.
10. Zhang, K., Dent, S.Y. Histone modifying enzymes and cancer: going beyond histones. J Cell Biochem 2005, 96(6): 1137-48.
11. Haberland, M., Montgomery, R.L., Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10(1): 32-42.
12. Rao, R., Fiskus, W., Yang, Y. et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008, 112(5): 1886-93.
13. Bali, P., Pranpat, M., Bradner, J. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280(29): 26729-34.
14. Huntly, B.J., Shigematsu, H., Deguchi, K. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6(6): 587-96.
15. Wang, J., Iwasaki, H., Krivtsov, A. et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 2005, 24(2): 368-81.
16. Iyer, N.G., Ozdag, H., Caldas, C. p300/CBP and cancer. Oncogene 2004, 23(24): 4225-31.
17. Avvakumov, N., Cote, J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 2007, 26(37): 5395-407.
18. Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A. et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471(7337): 189-95.
19. Johnstone, R.W., Licht, J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003, 4(1): 13-8.
20. West, A.C., Johnstone, R.W. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014, 124(1): 30-9.
21. Maes, K., Menu, E., Van Valckenborgh, E., Van Riet, I., Vanderkerken, K., De Bruyne, E. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers (Basel) 2013, 5(2): 430-61.
22. Rasheed, W., Bishton, M., Johnstone, R.W., Prince, H.M. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 2008, 8(3): 413-32.
23. Chen, P.C., Patil, V., Guerrant, W., Green, P., Oyelere, A.K. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorg Med Chem 2008, 16(9): 4839-53.
24. Finnin, M.S., Donigian, J.R., Cohen, A. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401(6749): 188-93.
25. Lavelle, D., Chen, Y.H., Hankewych, M., DeSimone, J. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001, 68(3): 170-8.
26. Catley, L., Weisberg, E., Tai, Y.T. et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003, 102(7): 2615-22.
27. Prince, H.M., Bishton, M.J., Harrison, S.J. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009, 15(12): 3958-69.
28. Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12(10): 1247-52.
29. Bertino, E.M., Otterson, G.A. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011, 20(8): 1151-8.
30. Lee, H.Z., Kwitkowski, V.E., Del Valle, P.L. et al. FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res 2015, 21(12): 2666-70.
31. Garnock-Jones, K.P. Panobinostat: first global approval. Drugs 2015, 75(6): 695-704.
32. Bianchi, G., Anderson, K.C. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin 2014, 64(6): 422-44.
33. Palumbo, A., Anderson, K. Multiple myeloma. N Engl J Med 2011, 364(11): 1046-60.
34. Mahindra, A., Hideshima, T., Anderson, K.C. Multiple myeloma: biology of the disease. Blood Rev 2010, 24(Suppl. 1): S5-11.
35. Bolli, N., Avet-Loiseau, H., Wedge, D.C. et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014, 5: 2997.
36. Corre, J., Munshi, N., Avet-Loiseau, H. Genetics of multiple myeloma: another heterogeneity level? Blood 2015, 125(12): 1870-6.
37. Martinez-Garcia, E., Popovic, R., Min, D.J. et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011, 117(1): 211-20.
38. Yang, P., Guo, L., Duan, Z.J. et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol 2012, 32(15): 3121-31.
39. Annunziata, C.M., Davis, R.E., Demchenko, Y. et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12(2): 115-30.
40. Keats, J.J., Fonseca, R., Chesi, M. et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12(2): 131-44.
41. Lohr, J.G., Stojanov, P., Carter, S.L. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014, 25(1): 91-101.
42. Chapman, M.A., Lawrence, M.S., Keats, J.J. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471(7339): 467-72.
43. Morgan, G.J., Kaiser, M.F. How to use new biology to guide therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2012, 2012: 342-9.
44. Teoh, P.J., Chung, T.H., Sebastian, S. et al. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia 2014, 28(10): 2066-74.
45. Egan, J.B., Shi, C.X., Tembe, W. et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012, 120(5): 1060-6.
46. Min, D.J., Ezponda, T., Kim, M.K. et al. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia 2013, 27(3): 686-94.
47. Pichiorri, F., Suh, S.S., Ladetto, M. et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008, 105(35): 12885-90.
48. Cho, J.H., Dimri, M., Dimri, G.P. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J Biol Chem 2015, 290(16): 10555-67.
49. Sampath, D., Zecevic, A., Ewald, B., Hayes, M., Liu, C., Marcucci, G., Plunkett, W. Panobinostat, an oral pan-histone deacetylase (HDAC) inhibitor activates a microRNA signature that targets Rad51 to attenuate homologous DNA repair and sensitize aml cells to sapacitabine. 55th Annu Meet Am Soc Hematol (December 7-10, New Orleans) 2013, Abst 822.
50. Henrici, A., Montalbano, R., Neureiter, D. et al. The pandeacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog 2015, 54(8): 585-97.
51. Vorhees, P., Bensinger, W.I., Berdeja, J. et al. ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and dexamethasone (dex), is well tolerated without dose limiting toxicity (DLT) in patients (Pts) with multiple myeloma (MM) at doses demonstrating biologic activity: Interim results of a phase 1b trial. 55th Annu Meet Am Soc Hematol (December 7-10, New Orleans) 2013, Abst 3190.
52. Boyault, C., Sadoul, K., Pabion, M., Khochbin, S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007, 26(37): 5468-76.
53. Kikuchi, J., Wada, T., Shimizu, R. et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010, 116(3): 406-17.
54. Shao, W., Growney, J.D., Feng, Y. et al. Potent anticancer activity of a pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models. Proc Am Assoc Cancer Res [99th Annu Meet Am Assoc Cancer Res (AACR) (April 12-16, San Diego) 2008] 2008, 49: Abst 735.
55. Atadja, P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009, 280(2): 233-41.
56. Maiso, P., Carvajal-Vergara, X., Ocio, E.M. et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006, 66(11): 5781-9.
57. Corrales-Medina, F.F., Manton, C.A., Orlowski, R.Z., Chandra, J. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leuk Res 2015, 39(3): 371-9.
58. Corrales-Medina, F.F., Bejar, D.E.E., Manton, C., Johnson, B., Irwin, M.E., Orlowski, R.Z., Chandra, J. Unique apoptotic effects of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. 55th Annu Meet Am Soc Hematol (December 7-10, New Orleans) 2013, Abst 3837.
59. Hasegawa, H., Yamada, Y., Tsukasaki, K. et al. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia 2011, 25(4): 575-87.
60. Gao, L., Gao, M., Yang, G. et al. Synergistic activity of carfilzomib and panobinostat in multiple myeloma cells via modulation of ROS generation and ERK1/2. Biomed Res Int 2015, 2015: 459052.
61. Bruzzese, F., Pucci, B., Milone, M.R. et al. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis 2013, 4: e878.
62. Mandawat, A., Fiskus, W., Buckley, K.M. et al. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood 2010, 116(24): 5306-15.
63. Kalushkova, A., Fryknas, M., Lemaire, M. et al. Polycomb target genes are silenced in multiple myeloma. PLoS One 2010, 5(7): e11483.
64. Marks, P.A. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 2010, 1799(10-12): 717-25.
65. Growney, J.D., Atadja, P., Shao, W. et al. Efficacy of panobinostat (LBH589) in multiple myeloma cell lines and in vivo mouse model: Tumor-specific cytotoxicity and protection of bone integrity in multiple myeloma. 49th Annu Meet Am Soc Hematol (December 8-11, Atlanta) 2007, Abst 1510.
66. Sanchez, E., Shen, J., Steinberg, J. et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res 2011, 35(3): 373-9.
67. Rajkumar, S.V., Jacobus, S., Callander, N.S. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11(1): 29-37.
68. Catley, L., Weisberg, E., Kiziltepe, T. et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108(10): 3441-9.
69. Ocio, E.M., Vilanova, D., Atadja, P. et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010, 95(5): 794-803.
70. Giles, F., Fischer, T., Cortes, J. et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006, 12(15): 4628-35.
71. Khot, A., Dickinson, M., Prince, H.M. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs 2013, 22(9): 1211-23.
72. Wolf, J.L., Siegel, D., Goldschmidt, H. et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012, 53(9): 1820-3.
73. San-Miguel, J.F., Richardson, P.G., Gunther, A. et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2013, 31(29): 3696-703.
74. Richardson, P.G., Schlossman, R.L., Alsina, M. et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013, 122(14): 2331-7.
75. San-Miguel, J.F., Hungria, V.T., Yoon, S.S. et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014, 15(11): 1195-206.
76. McBride, A., Klaus, J.O., Stockerl-Goldstein, K. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. Am J Health Syst Pharm 2015, 72(5): 353-60.
77. Jatin, J., Shah, S., Thomas, K. et al. Phase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myeloma. 54th Annu Meet Am Soc Hematol (December 8-11, Atlanta) 2012, Abst 4081.
78. Berdeja, J., Savona, M., Mace, J.R. et al. A single-arm, openlabel, multi-center phase I/II study of the combination of panobinostat and carfilzomib in patients (pts) with relapsed or relapse/refractory multiple myeloma (MM). 55th Annu Meet Am Soc Hematol (December 7-10, New Orleans) 2013, Abst 1937.
79. Mateos, M., Spencer, A., Taylor, K. et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). 46th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010, Abst 8030.
80. Biran, N., Shahnaz, S., Jagannath, S. et al. A phase II, singlecenter, open-label study of oral panobinostat in combination with lenalidomide and weekly dexamethasone in patients with multiple myeloma. 55th Annu Meet Am Soc Hematol (December 7-10, New Orleans) 2013, 5392.
81. Berenson, J.R., Hilger, J.D., Yellin, O. et al. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol 2014, 93(1): 89-98.
82. Orlowski, R.Z. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol 2013, 40(5): 634-51.
83. Govindaraj, C., Tan, P., Walker, P., Wei, A., Spencer, A., Plebanski, M. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res 2014, 20(3): 724-35.
84. Ria, R., Catacchio, I., Berardi, S. et al. HIF-1alpha of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res 2014, 20(4): 847-58.
85. Christiansen, A.J., West, A., Banks, K.M., Haynes, N.M., Teng, M.W., Smyth, M.J., Johnstone, R.W. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A 2011, 108(10): 4141-6.
86. Ellis, L., Pan, Y., Smyth, G.K. et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008, 14(14): 4500-10.
87. Treppendahl, M.B., Kristensen, L.S., Gronbaek, K. Predicting response to epigenetic therapy. J Clin Invest 2014, 124(1): 47-55.
88. Miyanaga, A., Gemma, A., Noro, R. et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008, 7(7): 1923-30.
89. Marquard, L., Gjerdrum, L.M., Christensen, I.J., Jensen, P.B., Sehested, M., Ralfkiaer, E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008, 53(3): 267-77.
90. Weichert, W., Roske, A., Niesporek, S. et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008, 14(6): 1669-77.